MOLECUL AR-GENETIC MARKERS OF THE THYROID GLAND'S FOLLICULAR CANCER DEVELOPMENT

Authors

  • Sazonov M .E. SI «V. Danilevsky Institute for Endocrine Pathology Problems of the NAMS of Ukraine», Kharkiv, Ukraine
  • Shtandel S. A. SI «V. Danilevsky Institute for Endocrine Pathology Problems of the NAMS of Ukraine», Kharkiv, Ukraine
  • Karachentsev Y. I. SI «V. Danilevsky Institute for Endocrine Pathology Problems of the NAMS of Ukraine», Kharkiv, Ukraine
  • Khaziev V. V. SI «V. Danilevsky Institute for Endocrine Pathology Problems of the NAMS of Ukraine», Kharkiv, Ukraine
  • Dubovik V. N. SI «V. Danilevsky Institute for Endocrine Pathology Problems of the NAMS of Ukraine», Kharkiv, Ukraine
  • Gopkalova I. V. SI «V. Danilevsky Institute for Endocrine Pathology Problems of the NAMS of Ukraine», Kharkiv, Ukraine

DOI:

https://doi.org/10.21856/j-PEP.2018.2.04

Keywords:

thyroid gland, follicular and papillary neoplasias, thyroid cancer, P12A and H449H mutations in the 2 and 6 exons of the PPARγ gene.

Abstract

The frequencies of P12A and H449H mutations in the 2 and 6 exons of the PPARγ gene in patients with
thyroid neoplasia were obtained. 128 thyroid tissue samples (29-follicular adenoma, 48-follicular cancer, 51-papillary cancer) were investigated for the presence of mutations. A differentiated contribution of the investigated
mutations to the manifestation of follicular carcinoma is shown. The mutations P12A and H449H in the 2 and
6 exons of the PPARγ gene are associated with the follicular structure of the neoplasia, but do not affect the malignant or benign variant of their development. The presented results are of direct practical importance. Since
the P12A mutation in the 2 exon of the PPARγ gene is specific to the follicular variant of the thyroid neoplasia,
its determination may be a useful additional method for differential diagnosis of nodal tumors of the thyroid

References

Mihnin AE. Prakticheskaja Onkologija 2007; 8 (1): 17-25.

Paches AI, Propp RM.Rak shhitovidnoj zhelezy, Moskva, 1995: 372 p.

Kazubskaja TP, Kozlova VM, Kondrat'eva TT, et al. Arhiv Patologii 2014; 5: 3-12.

Fagin JA. Mol Endocrinol 2002; 16: 903-911.

Castro P, Eknaes M, Teixeira MR, et al. J Pathol 2005; 206: 305-311.

Sobrinho-Simoes M, Preto A, Rocha AS, et al. Virchows Arch 2005; 447: 787-793.

Vasko V, Ferrand M, Di Cristofaro J, et al. J Clin Endocrinol Metab 2003; 88: 2745-2752.

Rochefort P, Caillou B, Michiels FM, et al. Oncogene 1996; 12: 111-118.

Santelli G, De FV, Portella G, et al. Cancer Res 1993; 53: 5523-5527.

Fjurer D. Mezhdunar Jendokrinol Zhurn 2007; 3 (9), available at: http://www.mif-ua.com/archive/article_ print/459.

Kroll TG, Sarraf P, Pecciarini L, et al. Science 2000; 289: 1357-1360.

Gregory PJ, Wang X, Allard BL, et al. Oncogene 200423: 3634-3641.

Au AY, McBride C, Wilhelm KG, et al. Endocrinology 2006; 147: 367-376.

Cheung L, Messina M, Gill A, et al. J Clin Endocrinol Metab 2003; 88: 354-357. 15. Marques AR, Espadinha C, Catarino AL, et al. J Clin

Endocrinol Metab 2002; 87: 3947-3952.

Nikiforova MN, Biddinger PW, Caudill CM, et al. Am J Surg Pathol 2002; 26: 1016-1023.

Nikiforova MN, Lynch RA, Biddinger PW, et al. J Clin Endocrinol Metab 2003; 88: 2318-2326.

Shtandel' SA, Haziev VV, Dubovik VN, et al. Innovacionnye tehnologii v jendokrinologii : tezisy III Vseros jendokrinol kongr s mezhdunar ucha-stiem, Moskva, 2017: 59.

Valve R, Sivenius K, Miettinen R, et al. J Clin Endocrinol Metab 1999; 84: 3708-3712.

Chung-Jen Y, Beamer BA, Negri C, et al. Bioch Biophys Res Commun 1997; 241 (2): 270-274.

Downloads

Published

2021-08-18

How to Cite

Sazonov, M. E. ., Shtandel, S. A. ., Karachentsev, Y. I. ., Khaziev, V. V. ., Dubovik, . V. N. ., & Gopkalova, I. V. . (2021). MOLECUL AR-GENETIC MARKERS OF THE THYROID GLAND’S FOLLICULAR CANCER DEVELOPMENT. Problems of Endocrine Pathology, 64(2), 25-30. https://doi.org/10.21856/j-PEP.2018.2.04

Issue

Section

CLINICAL ENDOCRINOLOGY

Most read articles by the same author(s)